InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more
InnoTherapy Inc (246960) - Total Liabilities
Latest total liabilities as of September 2025: ₩50.78 Billion KRW
Based on the latest financial reports, InnoTherapy Inc (246960) has total liabilities worth ₩50.78 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InnoTherapy Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InnoTherapy Inc Competitors by Total Liabilities
The table below lists competitors of InnoTherapy Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
Indonesia | Rp99.71 Billion |
|
Cubex Tubings Limited
NSE:CUBEXTUB
|
India | ₹726.86 Million |
|
3R Games SA
WAR:3RG
|
Poland | zł539.00K |
|
Superbag Company Limited
PINK:SUPBF
|
USA | $10.94 Billion |
|
Intouch Insight Ltd
OTCQX:INXSF
|
USA | $5.01 Million |
|
Cosigo Resources Ltd.
V:CSG
|
Canada | CA$368.22K |
|
Altamin Ltd
AU:AZI
|
Australia | AU$1.03 Million |
|
Tifa Finance Tbk
JK:TIFA
|
Indonesia | Rp591.62 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down InnoTherapy Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InnoTherapy Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InnoTherapy Inc (2015–2024)
The table below shows the annual total liabilities of InnoTherapy Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.54 Billion | -24.12% |
| 2023-12-31 | ₩11.26 Billion | -36.66% |
| 2022-12-31 | ₩17.77 Billion | -18.50% |
| 2021-12-31 | ₩21.80 Billion | +394.60% |
| 2020-12-31 | ₩4.41 Billion | +105.02% |
| 2019-12-31 | ₩2.15 Billion | +29.66% |
| 2018-12-31 | ₩1.66 Billion | +49.76% |
| 2017-12-31 | ₩1.11 Billion | +15.60% |
| 2016-12-31 | ₩957.90 Million | -93.32% |
| 2015-12-31 | ₩14.34 Billion | -- |